90 related articles for article (PubMed ID: 25030993)
21. Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation-Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma.
Kim CH; Kim SH; Park SY; Yoo J; Kim SK; Kim HK
Cancer Res Treat; 2015 Oct; 47(4):653-60. PubMed ID: 25687872
[TBL] [Abstract][Full Text] [Related]
22. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.
Villa C; Cagle PT; Johnson M; Patel JD; Yeldandi AV; Raj R; DeCamp MM; Raparia K
Arch Pathol Lab Med; 2014 Oct; 138(10):1353-7. PubMed ID: 24571650
[TBL] [Abstract][Full Text] [Related]
23. Correlation between status of epidermal growth factor receptor mutation and distant metastases of lung adenocarcinoma upon initial diagnosis based on 1063 patients in China.
Li H; Cao J; Zhang X; Song X; Wang W; Jia S; Li Z; Jia H; Cao X; Zhou W; Lian J; Han S; Yang W; Xi Y; Lian S; Jing H
Clin Exp Metastasis; 2017 Jan; 34(1):63-71. PubMed ID: 27888377
[TBL] [Abstract][Full Text] [Related]
24. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
[TBL] [Abstract][Full Text] [Related]
25. Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma.
Tseng JS; Yang TY; Tsai CR; Chen KC; Hsu KH; Tsai MH; Yu SL; Su KY; Chen JJ; Chang GC
J Thorac Oncol; 2015 Apr; 10(4):603-10. PubMed ID: 25514801
[TBL] [Abstract][Full Text] [Related]
26. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
Jeon JH; Kang CH; Kim HS; Seong YW; Park IK; Kim YT
Eur J Cardiothorac Surg; 2015 Mar; 47(3):556-62. PubMed ID: 24760387
[TBL] [Abstract][Full Text] [Related]
27. [Relationship between histopathologic characteristics and epidermal growth factor receptor mutation in lung adenocarcinoma].
Wang K; Gong H; Li X; Yang Z; Cao P; Wand C; Jiang Y; Wang H; Wang Y; Zhang G
Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):170-4. PubMed ID: 26268750
[TBL] [Abstract][Full Text] [Related]
28. Lung adenocarcinoma: Assessment of epidermal growth factor receptor mutation status based on extended models of diffusion-weighted image.
Yuan M; Pu XH; Xu XQ; Zhang YD; Zhong Y; Li H; Wu JF; Yu TF
J Magn Reson Imaging; 2017 Jul; 46(1):281-289. PubMed ID: 28054731
[TBL] [Abstract][Full Text] [Related]
29. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
[TBL] [Abstract][Full Text] [Related]
30. Correlation between computed tomography findings and epidermal growth factor receptor and KRAS gene mutations in patients with pulmonary adenocarcinoma.
Sugano M; Shimizu K; Nakano T; Kakegawa S; Miyamae Y; Kaira K; Araki T; Kamiyoshihara M; Kawashima O; Takeyoshi I
Oncol Rep; 2011 Nov; 26(5):1205-11. PubMed ID: 21811765
[TBL] [Abstract][Full Text] [Related]
31. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
[TBL] [Abstract][Full Text] [Related]
32. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
[TBL] [Abstract][Full Text] [Related]
34. Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma.
Ma X; Zhu H; Guo H; Han A; Wang H; Jing W; Zhang Y; Kong L; Yu J
Oncotarget; 2016 Dec; 7(49):81906-81917. PubMed ID: 27626317
[TBL] [Abstract][Full Text] [Related]
35. Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas.
Shoji F; Yoshino I; Yano T; Kometani T; Ohba T; Kouso H; Takenaka T; Miura N; Okazaki H; Maehara Y
Cancer; 2007 Dec; 110(12):2793-8. PubMed ID: 17941001
[TBL] [Abstract][Full Text] [Related]
36. Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score.
Lee DW; Shin DY; Kim JW; Keam B; Kim TM; Kim HJ; Kim DW; Wu HG; Paek SH; Kim YW; Heo DS; Kim DG; Lee SH
Lung Cancer; 2014 Dec; 86(3):363-8. PubMed ID: 25453849
[TBL] [Abstract][Full Text] [Related]
37. Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Jain A; Lim C; Gan EM; Ng DZ; Ng QS; Ang MK; Takano A; Chan KS; Tan WM; Kanesvaran R; Toh CK; Loo CM; Hsu AA; Devanand A; Lim CH; Koong HN; Koh T; Fong KW; Yap SP; Kim SW; Chowbay B; Oon L; Lim KH; Lim WT; Tan EH; Tan DS
PLoS One; 2015; 10(5):e0123587. PubMed ID: 25955322
[TBL] [Abstract][Full Text] [Related]
38. Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients.
Hashida S; Soh J; Toyooka S; Tanaka T; Furukawa M; Shien K; Yamamoto H; Asano H; Tsukuda K; Hagiwara K; Miyoshi S
Oncol Rep; 2014 Jul; 32(1):145-52. PubMed ID: 24842519
[TBL] [Abstract][Full Text] [Related]
39. The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas.
Cho J; Choi SM; Lee J; Lee CH; Lee SM; Yim JJ; Chung DH; Yoo CG; Kim YW; Han SK; Park YS
PLoS One; 2016; 11(11):e0166821. PubMed ID: 27861565
[TBL] [Abstract][Full Text] [Related]
40. [Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma].
Zhang H; Yang X; Qin N; Li X; Yang H; Nong J; Lv J; Wu Y; Zhang Q; Zhang X; Wang J; Zhou L; Zhang S
Zhongguo Fei Ai Za Zhi; 2015 Nov; 18(11):686-90. PubMed ID: 26582224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
